EcoDrugPlus

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSOMEG00000015715
Gene Symbol: LOC112162355
2 Cross references
214 Possible Orthologues:

Glutamate Receptor Ionotropic, Kainate 1-Like

Ensembl ID : ENSOMEG00000014807
Gene Symbol: LOC112142879
2 Cross references
245 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSOMEG00000012345
Gene Symbol: GRIA1A
1 Cross references
251 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b, Genome Duplicate B

Ensembl ID : ENSOMEG00000016111
Gene Symbol: GRIN2BB
1 Cross references
250 Possible Orthologues:

Glutamate Receptor, Metabotropic 5a

Ensembl ID : ENSOMEG00000014934
Gene Symbol: GRM5A
1 Cross references
211 Possible Orthologues:

Glutamate Receptor, Metabotropic 5b

Ensembl ID : ENSOMEG00000002640
Gene Symbol: GRM5B
1 Cross references
214 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha A

Ensembl ID : ENSOMEG00000017463
Gene Symbol: GSK3AA
1 Cross references
187 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSOMEG00000008470
Gene Symbol: GSK3B
3 Cross references
222 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSOMEG00000000943
Gene Symbol: LOC112143678
3 Cross references
186 Possible Orthologues:

Golgin Subfamily A Member 7-Like

Ensembl ID : ENSOMEG00000002155
Gene Symbol: LOC112145658
3 Cross references
398 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSOMEG00000016558
Gene Symbol: GHSR
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSOMEG00000009569
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).